All In Biotech

Drug Trial Radar · NCT07405606

Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder

Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Mar 23, 2026

Primary completion

Mar 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Centre for Addiction and Mental HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine the safety and efficacy of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD). The main question it aims to answer is: \- What is the feasibility and safety of administering PAT in adults with MDD-AUD by evaluating recruitment, retention, tolerability, and safety? Researchers will compare the psilocybin (25 mg) and placebo groups to see if there are any significant differences in frequency of dropouts or serious adverse events. Participants will: * be randomized to receive either psilocybin (25 mg) or placebo * visit the site (in-person and remotely) for a total of 14 times to complete study tasks * receive psilocybin-assisted therapy (PAT) at five various timepoints

Conditions

  • Major Depressive Disorder (MDD)
  • Alcohol Use Disorder (AUD)

Interventions

  • Psilocybin 25 mgDrug

    Participants will orally consume Psilocybin (25 mg) with water.

  • PlaceboDrug

    Participants will orally consume placebo matching the intervention with water.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AdherenceTime frame: Week 2 (Visit 4)
  2. Montgomery-Asberg Depression Rating Scale (MADRS)Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
  3. Hamilton Depression Rating Scale (HAMD-17)Time frame: 4-week post dose; week 26.
  4. Quick Inventory of Depressive Symptomatology - Self Report (QUIDS-SR)Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
  5. Alcohol Timeline Followback (TLFB)Time frame: Baseline; week 2 (visit 3); 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
  6. Clinical Institute Withdrawal Assessment (CIWA)Time frame: Baseline; week 2 (visit 3); week 2 (visit 4); 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
  7. Prediction of Alcohol Withdrawal Severity Scale (PAWSS)Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
  8. Penn Alcohol Craving Scale (PACS)Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
  9. Addiction Severity Index (ASI)Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Addiction and Mental Health

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.